GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genomma Lab Internacional SAB de CV (OTCPK:GNMLF) » Definitions » PEG Ratio

GNMLF (Genomma Lab InternacionalB de CV) PEG Ratio : 2.23 (As of Dec. 15, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Genomma Lab InternacionalB de CV PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Genomma Lab InternacionalB de CV's PE Ratio without NRI is 12.96. Genomma Lab InternacionalB de CV's 5-Year EBITDA growth rate is 5.80%. Therefore, Genomma Lab InternacionalB de CV's PEG Ratio for today is 2.23.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Genomma Lab InternacionalB de CV's PEG Ratio or its related term are showing as below:

GNMLF' s PEG Ratio Range Over the Past 10 Years
Min: 0.45   Med: 1.46   Max: 2.61
Current: 2.61


During the past 13 years, Genomma Lab InternacionalB de CV's highest PEG Ratio was 2.61. The lowest was 0.45. And the median was 1.46.


GNMLF's PEG Ratio is ranked worse than
63.29% of 365 companies
in the Drug Manufacturers industry
Industry Median: 1.93 vs GNMLF: 2.61

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Genomma Lab InternacionalB de CV PEG Ratio Historical Data

The historical data trend for Genomma Lab InternacionalB de CV's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomma Lab InternacionalB de CV PEG Ratio Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 2.31 1.53

Genomma Lab InternacionalB de CV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.15 1.53 1.85 1.79 1.90

Competitive Comparison of Genomma Lab InternacionalB de CV's PEG Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomma Lab InternacionalB de CV's PEG Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's PEG Ratio falls into.



Genomma Lab InternacionalB de CV PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Genomma Lab InternacionalB de CV's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=12.959183673469/5.80
=2.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


Genomma Lab InternacionalB de CV  (OTCPK:GNMLF) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Genomma Lab InternacionalB de CV PEG Ratio Related Terms

Thank you for viewing the detailed overview of Genomma Lab InternacionalB de CV's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genomma Lab InternacionalB de CV Business Description

Traded in Other Exchanges
Address
Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.